| First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy. | |
| | |
MedLine Citation:
|
PMID: 18303489 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Converging lines of evidence suggest pathophysiology of alpha7 nicotinic acetylcholine receptors (alpha7 nAChRs) in schizophrenia. This pilot study was designed to test the tolerability, safety, and preliminary efficacy of chronic administration of an alpha7 nAChR agonist strategy involving combination treatment of cytidine diphosphocholine (CDP-choline; 2 g/d), a dietary source of the alpha7 nAChR agonist choline, and galantamine (24 mg/d), a positive allosteric modulator of nAChRs that was prescribed to prevent choline from becoming a functional antagonist and improve the efficiency of coupling the binding of choline to channel opening. The combination of CDP-choline and galantamine was administered to 6 schizophrenic patients with residual symptoms in a 12-week, open-label trial. Patients were maintained on stable dose regimens of antipsychotic medications for 4 weeks before study entry and for the trial duration. All reached target doses of both agents and completed the trial. Transient side effects resolved without slowing of dose titration. Gastrointestinal adverse effects were most common. Of the 6 patients, 5 showed reduction in Clinical Global Impressions severity scores and Positive and Negative Syndrome Scale total scores. Three patients requested continuation of the adjunctive combination at the end of the trial. These results suggest further investigation of the combination of CDP-choline and galantamine as an alpha7 nAChR agonist intervention. |
| | |
Authors:
|
Stephen I Deutsch; Barbara L Schwartz; Nina R Schooler; Richard B Rosse; John Mastropaolo; Brooke Gaskins |
Related Documents
:
|
8508709 - Prospective, randomized, investigator-blind trial of helicobacter pylori infection trea... 9663839 - Four-day quadruple therapy as a routine treatment for helicobacter pylori infection. 22083619 - Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopath... 7980309 - Randomized prospective intervention study of human cervical wart virus infection. 21904009 - Preoperative predictors for non-copers to pass return to sports criteria after acl reco... 21965229 - Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. 1576619 - Influence of three-day antimicrobial therapy and lactobacillus vaginal suppositories on... 18336919 - Treatment of post-traumatic stress disorder with eye movement desensitization and repro... 20304219 - Hepatitis c virus recurrence after liver transplantation: analysis of factors related t... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical neuropharmacology Volume: 31 ISSN: 1537-162X ISO Abbreviation: Clin Neuropharmacol Publication Date: 2008 Jan-Feb |
Date Detail:
|
Created Date: 2008-02-27 Completed Date: 2008-03-11 Revised Date: 2010-06-04 |
Medline Journal Info:
|
Nlm Unique ID: 7607910 Medline TA: Clin Neuropharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 34-9 Citation Subset: IM |
Affiliation:
|
Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington DC 20422, USA. Stephen.Deutsch@med.va.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Cytidine Diphosphate Choline / therapeutic use* Female Galantamine / therapeutic use* Humans Male Middle Aged Nicotinic Agonists / therapeutic use* Nootropic Agents / therapeutic use Pilot Projects Receptors, Nicotinic / metabolism* Schizophrenia / drug therapy*, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Nicotinic Agonists; 0/Nootropic Agents; 0/Receptors, Nicotinic; 0/alpha7 nicotinic acetylcholine receptor; 357-70-0/Galantamine; 987-78-0/Cytidine Diphosphate Choline |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.
Next Document: Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia.